In the ongoing denosumab biosimilar race, Sandoz has reached one of the milestones with its Jubbonti version, as the biosimilar to Amgen’s Prolia was recently approved by Health Canada.
Jubbonti, a human monoclonal antibody and RANK ligand inhibitor, should be available for Canadians in the coming months as a 60mg/mL solution in a single-use prefilled
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?